Tokyo, Dec. 5 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059982) titled 'Validation of optimal hormone levels in transgender women' on Dec. 4.
Study Type:
Observational
Primary Sponsor:
Institute - Sapporo Medical University
Condition:
Condition - transgender women
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To validate optimal testosterone and estradiol levels in transgender women
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male
Key inclusion criteria - Transgender women undergoing gender-affirming hormone therapy
Key exclusion criteria - Transgender women who undergo gender-affiming surgery
Target Size - 80
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2025 Year 06 Month 15 Day
Date of IRB - 2025 Year 07 Month 10 Day
Anticipated trial start date - 2025 Year 07 Month 23 Day
Last follow-up date - 2030 Year 04 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068573
Disclaimer: Curated by HT Syndication.
